Brought to you by 
Bristol-Myers Squibb acquires Celgene for $74bn, deepening strength in oncology
Jan 2019
Executive Summary
In the fourth-largest biopharma acquisition to date, Bristol-Myers Squibb Co. bought top-tier public biotech Celgene Corp. for $74bn. For each Celgene share, BMS will issue one of its shares (valued at $50 each) and pay $50 in cash, equating to a per-share price of $100, or a 58% premium. Celgene also gets one tradeable contingent value right (CVR) for each of its shares, providing additional payments of $9 in cash based on regulatory milestones. At closing, BMS stockholders will own 69% of the combined entity, and Celgene shareholders the rest.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Full Acquisition
- Payment Includes Cash
- Includes Earnout
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol-Myers Squibb acquires Celgene for $74bn, deepening strength in oncology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice